Leukemia Trial Results
Trials Point to More Treatment Options for Chronic Myeloid Leukemia
(Posted: 07/08/2010) - Two studies published online June 5, 2010, in the New England Journal of Medicine found that two second-generation kinase inhibitors outperform imatinib, at least over the short term, in patients with chronic myelogenous leukemia.
Post-Remission Therapy that Includes All-Trans Retinoic Acid is Effective for Acute Promyelocytic Leukemia
(Posted: 07/02/2010) - A study published online April 14, 2010, in Blood finds that modified consolidation therapy regimens that include all-trans retinoic acid may be less toxic and as effective for patients with low- and medium-risk acute promyelocytic leukemia and may reduce relapse rates for patients with high-risk disease.
Young Adults with Acute Lymphoblastic Leukemia Do Well on Intensified Pediatric Chemotherapy Regimen
(Posted: 11/30/2009) - Adolescents and young adults with acute lymphoblastic leukemia lived longer when treated with an intensified multi-drug chemotherapy regimen that is used to treat younger children, according to the November 1, 2009, Journal of Clinical Oncology.
Imatinib Added to Chemotherapy Keeps Disease in Check for Longer in Children with Rare Form of Acute Lymphoblastic Leukemia
(Posted: 11/30/2009) - The addition of the targeted drug imatinib to chemotherapy for children with an uncommon form of acute lymphoblastic leukemia (ALL) dramatically improved the length of time the disease remained in remission, according to the November 1, 2009, Journal of Clinical Oncology.
Donated Stem Cell Transplants Better than Self-transplants for Most Patients with AML
(Posted: 07/23/2009) - Evidence from a meta-analysis of prospective clinical trials supports the use of donated (or allograft) stem cell transplants to treat most individuals with acute myeloid leukemia, according to the June 10, 2009, Journal of the American Medical Association.
(Posted: 07/08/2010) - Two studies published online June 5, 2010, in the New England Journal of Medicine found that two second-generation kinase inhibitors outperform imatinib, at least over the short term, in patients with chronic myelogenous leukemia.
Post-Remission Therapy that Includes All-Trans Retinoic Acid is Effective for Acute Promyelocytic Leukemia
(Posted: 07/02/2010) - A study published online April 14, 2010, in Blood finds that modified consolidation therapy regimens that include all-trans retinoic acid may be less toxic and as effective for patients with low- and medium-risk acute promyelocytic leukemia and may reduce relapse rates for patients with high-risk disease.
Young Adults with Acute Lymphoblastic Leukemia Do Well on Intensified Pediatric Chemotherapy Regimen
(Posted: 11/30/2009) - Adolescents and young adults with acute lymphoblastic leukemia lived longer when treated with an intensified multi-drug chemotherapy regimen that is used to treat younger children, according to the November 1, 2009, Journal of Clinical Oncology.
Imatinib Added to Chemotherapy Keeps Disease in Check for Longer in Children with Rare Form of Acute Lymphoblastic Leukemia
(Posted: 11/30/2009) - The addition of the targeted drug imatinib to chemotherapy for children with an uncommon form of acute lymphoblastic leukemia (ALL) dramatically improved the length of time the disease remained in remission, according to the November 1, 2009, Journal of Clinical Oncology.
Donated Stem Cell Transplants Better than Self-transplants for Most Patients with AML
(Posted: 07/23/2009) - Evidence from a meta-analysis of prospective clinical trials supports the use of donated (or allograft) stem cell transplants to treat most individuals with acute myeloid leukemia, according to the June 10, 2009, Journal of the American Medical Association.
